The study addresses the safety, utilisation and effectiveness of Obizur in the treatment of bleeding episodes in real-life clinical practice in Europe and the United States.



Eligible Ages
Over 18 Years
Eligible Genders
Accepts Healthy Volunteers

Inclusion Criteria

  • Adult participant (or legal representative) is willing to provide informed consent
  • Participant is being treated or was treated (treatment initiation within 30 days) with Obizur in routine clinical practice

Exclusion Criteria

  • Participant has known anaphylactic reactions to the active substance, hamster protein or to any of the following excipients: Polysorbate 80; sodium chloride; calcium chloride dihydrate; sucrose; Tris Base; Tris HCl; Tri-sodium citrate dihydrate; sterilized water for injections
  • Participant has participated in a clinical study involving a medicinal product or device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving a medicinal product or device at study entry

Study Design

Study Type
Observational Model
Time Perspective

Arm Groups

ArmDescriptionAssigned Intervention
OBIZUR participants Participants previously treated with OBIZUR and continue to be treated with OBIZUR during the study.
  • Biological: OBIZUR
    Treating physician will determine treatment regimen and frequency of laboratory and clinical assessments according to routine clinical practice.
    Other names:
    • Recombinant pFVIII
    • Porcine Sequence
    • rpFVIII
    • Antihemophilic Factor (Recombinant)

Recruiting Locations

The University of Texas Health Science Center at Houston
Houston, Texas 77030

More Details

Baxalta now part of Shire

Study Contact

Shire Contact
+1 866 842 5335


Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.